In vivo CYP3A activity in palliative care patients
Conditions
Interventions
Group 1: A four hour pharmacokinetic profile after oral administration of the marker substance (microdose of 10µg midazolam) will be obtained from each enrolled patient. Plasma concentrations of midaz
Sponsors
Universitätsklinikum Heidelberg, Klinik für Anäthesiologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Every patient admitted on the ward who is at least 18 years of age could be enrolled. Hemoglobin should be >7.5 g/dL.
Exclusion criteria
Exclusion criteria: Exclusion criteria are the need of red blood cells transfusions on a regular basis, inability to communicate well with the investigator due to language problems or poor mental development
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study aims to find out how the CYP3A activity is in individual patients with various genetic predisposition and specific underlying diseases on a palliative care unit during real clinical conditions in comparison to healthy volunteers or other patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome of this study is to find out if dose adjustment for palliative care patients is necessary if CYP3A inductors or inhibitors are combined with CYP3A substrates? | — |
Countries
Germany
Contacts
Public ContactMarcus Geist
Universitätsklinikum Heidelberg, Klinik für Anäthesiologie
Outcome results
None listed